BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29682327)

  • 1. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.
    Khier S; Lohan L
    Future Sci OA; 2018 Apr; 4(4):FSO295. PubMed ID: 29682327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
    Zhang W; Xia W; Lv Z; Ni C; Xin Y; Yang L
    Cell Physiol Biochem; 2017; 41(2):755-768. PubMed ID: 28214887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Biopsy: From Basic Research to Clinical Practice.
    Macías M; Alegre E; Díaz-Lagares A; Patiño A; Pérez-Gracia JL; Sanmamed M; López-López R; Varo N; González A
    Adv Clin Chem; 2018; 83():73-119. PubMed ID: 29304904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.
    Almufti R; Wilbaux M; Oza A; Henin E; Freyer G; Tod M; Colomban O; You B
    Ann Oncol; 2014 Jan; 25(1):41-56. PubMed ID: 24356619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
    Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
    World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Metastatic Cascade as the Basis for Liquid Biopsy Development.
    Eslami-S Z; Cortés-Hernández LE; Alix-Panabières C
    Front Oncol; 2020; 10():1055. PubMed ID: 32850309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.
    Chen Q; Zhang ZH; Wang S; Lang JH
    Onco Targets Ther; 2019; 12():11517-11530. PubMed ID: 31920340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
    Kerachian MA; Poudineh A; Thiery JP
    Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
    He WS; Bishop KS
    Expert Rev Mol Diagn; 2016 Aug; 16(8):839-52. PubMed ID: 27254598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy.
    Oellerich M; Schütz E; Beck J; Walson PD
    Ther Drug Monit; 2019 Apr; 41(2):115-120. PubMed ID: 30883505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.
    Gu Y; Wan C; Qiu J; Cui Y; Jiang T; Zhuang Z
    PLoS One; 2020; 15(2):e0224001. PubMed ID: 32027658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies.
    Esposito A; Criscitiello C; Locatelli M; Milano M; Curigliano G
    Pharmacol Ther; 2016 Jan; 157():120-4. PubMed ID: 26615782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
    Vymetalkova V; Cervena K; Bartu L; Vodicka P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of liquid biopsy in precision medicine: opportunities and challenges.
    Wang J; Chang S; Li G; Sun Y
    Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology.
    Mathai RA; Vidya RVS; Reddy BS; Thomas L; Udupa K; Kolesar J; Rao M
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30889786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.